paclitaxel has been researched along with Encephalopathy, Toxic in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (30.16) | 29.6817 |
| 2010's | 25 (39.68) | 24.3611 |
| 2020's | 19 (30.16) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, SY; Gao, H; Han, S; Ji, X; Jung, S; Liu, X; Luo, B; Mao, Y; Ren, H; Shen, C; Shi, P; Wang, JW; Yeo, XY; Yi, Z | 1 |
| Alberti, P; Alemany, M; Argyriou, AA; Bruna, J; Cavaletti, G; Dinoto, A; Ferrari, S; Kalofonos, HP; Kalofonou, F; Karteri, S; Mariotto, S; Stradella, A; Velasco, R; Velissaris, D | 1 |
| Elshafiey, RA; Elzawawy, S; Ghoneim, A; Mostafa, TM; Werida, RH | 1 |
| Antonio-Aguirre, B; Armenta-Quiroga, AS; Catalán, R; Espinosa-Fernandez, JR; Estrada-Mena, FJ; Freyria, A; Guijosa, A; Ortega-Treviño, MF; Perez-Ortiz, AC; Villarreal-Garza, C | 1 |
| Chakrabarti, P; Dehghani, M; Gholamzadeh, MJ; Kamali, AM; Mousavi, SZ; Nami, M; Owrangi, M; Vasaghi Gharamaleki, M | 1 |
| Da, H; Ding, Z; Fang, J; He, Y; Wang, Z; Wu, Q; Xi, J; Xu, Y; Zhang, F; Zhang, Z; Zhao, H | 1 |
| Alberti, P; Ballarini, E; Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Crippa, L; Marmiroli, P; Monza, L; Pozzi, E; Rodriguez-Menendez, V | 1 |
| Aghabozorgi, R; Babaee, M; Hashemi, M; Hesam, M; Rayegani, SM; Zahed, G | 1 |
| Gu, WY; Han, C; Xyu, L; Zeng, WY; Zhang, Y | 1 |
| Arizono, K; Hiroka, Y; Ichikawa, N; Miyasaka, K; Mizukami, M; Niwa, K; Sakaguchi, Y | 1 |
| Anastasio, MK; Erkanli, A; Havrilesky, LJ; Hayes, T; Moss, HA; Scott, A; Shah, S; Unnithan, S | 1 |
| Ang, E; Ang, S; Bandla, A; Chan, A; Chan, G; Hairom, Z; Huang, Y; Kumarakulasinghe, NB; Lee, SC; Lee, YM; Lim, JSJ; Magarajah, G; Ngoi, N; Sundar, R; Tan, S; Thakor, N; Wilder-Smith, E; Wong, A | 1 |
| Hirata, T; Nishina, M; Ozaki, S; Shigematsu, H; Yasui, D | 1 |
| Alberti, P; Blennow, K; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Fumagalli, G; Marmiroli, P; Meregalli, C; Monza, L; Pozzi, E; Zetterberg, H | 1 |
| Alberti, P; Ballarini, E; Canta, A; Cavaletti, G; Chiorazzi, A; Fumagalli, G; Guarnieri, C; Marmiroli, P; Meregalli, C; Monza, L; Oggioni, N; Pozzi, E; Rodriguez-Menendez, V; Scali, C | 1 |
| Boyle, F; Friedlander, M; Goldstein, D; Harrison, M; Kiernan, MC; Li, T; Park, SB; Timmins, HC; Trinh, T | 1 |
| Au, K; Battaglini, E; Geelan-Small, P; Goldstein, D; Grimison, P; Henderson, RD; Ke, H; Li, T; Marker, J; Mizrahi, D; Park, SB; Timmins, HC; Trinh, T; Wall, B; Wyld, D | 1 |
| Albert, V; Bobylev, I; Joshi, AR; Klein, I; Lehmann, HC; Müller, C; Wiesen, MHJ | 1 |
| Al-Mahayri, ZN; AlAhmad, MM; Ali, BR | 1 |
| Asher, R; Beale, P; Friedlander, M; Kwok, JB; Lee, CK; Park, SB; Selle, F | 1 |
| Albain, KS; Crew, KD; Fehrenbacher, L; Fisch, MJ; Greenlee, H; Hershman, DL; Lew, DL; Lynn Henry, N; Minasian, LM; Moinpour, CM; Till, C; Unger, JM; Wade, JL; Wong, SF | 1 |
| Boehmerle, W; Endres, M; Harms, C; Huehnchen, P; Lee, SLL | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| Choi, BY; Suh, SW | 1 |
| Goldstein, D; McCrary, JM; Park, SB; Tan, AC; Trinh, T | 1 |
| Alexandre, J; Copel, L; Dauba, J; Delva, R; Joly, F; Largillier, R; Meunier, J; Pujade-Lauraine, E; Ray-Coquard, I; Spaeth, D; Weber, B; Yazbek, G | 1 |
| de Bruijn, P; de Graan, AJ; de Raaf, PJ; Elens, L; Engels, FK; Eskens, FA; Friberg, LE; Mathijssen, RH; Sparreboom, A; Sprowl, JA; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Chen, W; Höke, A; Mi, R; Reed, N; Zhou, C; Zhu, J | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| da Silva Simão, DA; de Paula Lima, ED; Souza, RS; Teixeira, AL | 1 |
| Fang, Y; Shi, MQ; Wang, L; Xia, GH | 1 |
| Baty, F; de Graan, AJ; Jaehde, U; Joerger, M; Kraff, S; Mathijssen, RH; Nieuweboer, AJ; van Schaik, RH | 1 |
| Amant, F; Debruyne, PR; Despierre, E; Lambrechts, D; Lambrechts, S; Leunen, K; Luyten, D; Neven, P; Renard, V; Smeets, D; Van Nieuwenhuysen, E; Vergote, I; Vroman, P | 1 |
| Apellániz-Ruiz, M; Bergmann, TK; Brøsen, K; Green, H; Ingelman-Sundberg, M; Johansson, I; Lee, MY; Rodríguez-Antona, C; Vikingsson, S | 1 |
| Backman, J; Bergmann, TK; Brosen, K; Filppula, AM; Launiainen, T; Nielsen, F | 1 |
| Boven, E; Frederiks, CN; Guchelaar, HJ; Lam, SW | 1 |
| Aranishi, T; Hausheer, FH; Hisamatsu, K; Kuroi, K; Masuda, N; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Takeuchi, A | 1 |
| Avezza, F; Bossi, M; Canta, A; Carozzi, V; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Nicolini, G; Oggioni, N; Rodriguez-Menendez, V | 1 |
| Agthong, S; Chentanez, V; Duangmardphon, N; Huanmanop, T; Kaewsema, A; Maneesri, S; Thanomsridejchai, N | 1 |
| Andras, M; Dabby, R; Fishman, A; Gadoth, N; Karmon, Y; Levavi, H; Levi, T; Loven, D; Sabach, G; Zart, R | 1 |
| Argyriou, AA | 1 |
| Minami, H; Mukohara, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N | 1 |
| Cascón, A; García-Donas, J; Hernando, S; Hurtado, A; Jara, C; Landa, I; Leandro-García, LJ; Leskelä, S; López-Jiménez, E; Martínez, A; Milne, RL; Montero-Conde, C; Robledo, M; Rodríguez-Antona, C; Vicario, JC | 1 |
| Bergin, P; Damianovich, D; Findlay, M; Hanning, F; Hill, A; McKeage, MJ; Thompson, P | 1 |
| Fujimoto, S; Fukuda, T; Furihata, T; Hase, I; Ishii, Y; Kikkawa, Y; Miyoshi, M; Okazaki, K; Takizawa, H; Yamada, I | 1 |
| Bhattacharya, MR; DiAntonio, A; Ebstein, SY; Gerdts, J; Milbrandt, J; Naylor, SA; Royse, EX; Sasaki, Y | 1 |
| Aranishi, T; Hausheer, FH; Katsumata, N; Kuranami, M; Kuroi, K; Makino, H; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Abe, K; Chiba, T; Hama, T; Katagiri, N; Kawakami, K; Saduka, M; Taguchi, K; Utsunomiya, I | 1 |
| Boyette-Davis, JA; Bruel, BM; Cata, JP; Dougherty, PM; Driver, LC; Kennedy, WR; Mooring, DL; Novy, DM; Wendelschafer-Crabb, G | 1 |
| Durand, JP; Goldwasser, F | 1 |
| Kamura, T; Kawagoe, H; Kumagai, S; Matsuo, G; Nishida, T; Nishio, S; Ota, S; Sugiyama, T; Ushijima, K | 1 |
| Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Wang, S; Yang, D; Zhang, J; Zhou, B | 1 |
| Arné-Bès, MC | 1 |
| Bogliun, G; Buda, A; Cavaletti, G; Colombo, N; Cundari, S; Fei, F; Franchi, D; La Presa, MT; Lissoni, A; Marzorati, L; Piatti, M; Zanna, C; Zincone, A | 1 |
| Burges, A; du Bois, A; Heilmann, V; Hilpert, F; Richter, B; Rossner, D; Späthe, K; Stähle, A; Tomé, O | 1 |
| Bota, S; Lachkar, S; Nouvet, G; Thiberville, L | 1 |
| Camara, O; Christiansen, B; Elling, D; Gebauer, G; Keil, E; Klare, P; Ledwon, P; Lichtenegger, W; Mustea, A; Schwarz, M; Sehouli, J; Stengel, D | 1 |
| Connor, B; Dragunow, M; Jamieson, SM; Liu, JJ; McKeage, MJ | 1 |
| Choi, BS; Robins, HI | 1 |
| Kajiki, M; Kobayashi, TR; Kuriyama, H; Sugahara, S | 1 |
| Eguchi, K; Kato, H; Mimura, Y; Ogawa, T | 1 |
| Arditti, J; Catalin, J; Chastagner, P; Doz, F; Frappaz, D; Gentet, JC; Iliadis, A; Moretti, S; Pein, F; Tellingen, OV; Vassal, G | 1 |
| Brant, J; Nielsen, E | 1 |
7 review(s) available for paclitaxel and Encephalopathy, Toxic
| Article | Year |
|---|---|
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Topics: Breast Neoplasms; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Female; Genetic Markers; Humans; Liver-Specific Organic Anion Transporter 1; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Taxoids | 2022 |
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Genome-Wide Association Study; Humans; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Pharmacogenetics | 2021 |
Antimicrotubule Agent-Induced Zinc Neurotoxicity.
Topics: Animals; Cation Transport Proteins; Cell Death; Cognitive Dysfunction; Colchicine; Disease Models, Animal; Hippocampus; Humans; Mice; Microtubules; Neurogenesis; Neurons; Neurotoxicity Syndromes; Paclitaxel; Presynaptic Terminals; Tubulin Modulators; Vincristine | 2018 |
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Docetaxel; Gastrointestinal Diseases; Hematologic Diseases; Humans; Neurotoxicity Syndromes; Paclitaxel; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor, EphA5; Receptor, EphA6; Taxoids; Tubulin | 2015 |
[Neurotoxic effects of medications: an update].
Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans; Interferon-alpha; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thalidomide | 2004 |
[Acute encephalopathy after infusion of paclitaxel].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Brain Diseases; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Paclitaxel | 2006 |
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxicity Syndromes; Nursing Assessment; Oncology Nursing; Paclitaxel; Vinca Alkaloids | 2002 |
16 trial(s) available for paclitaxel and Encephalopathy, Toxic
| Article | Year |
|---|---|
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Doxorubicin; Female; Humans; Neurotensin; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Thioctic Acid; Tumor Necrosis Factor-alpha | 2022 |
Efficacy of Duloxetine on electrodiagnostic findings of Paclitaxel-induced peripheral neuropathy, does it have a prophylactic effect? A randomized clinical trial.
Topics: Breast Neoplasms; Duloxetine Hydrochloride; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Topics: Antineoplastic Agents; Female; Genital Neoplasms, Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Topics: Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Surveys and Questionnaires | 2020 |
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Neurotoxicity Syndromes; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Physicians; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Survival Rate; Young Adult | 2017 |
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Topics: Acetylcarnitine; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Placebos; Taxoids; Treatment Outcome | 2018 |
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Erythropoietin; Female; France; Humans; Middle Aged; Neuroprotective Agents; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Surveys and Questionnaires; Translations | 2013 |
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Double-Blind Method; Female; Glutamic Acid; Humans; Middle Aged; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Linear Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Neurotoxicity Syndromes; Paclitaxel | 2010 |
Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis | 2011 |
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires; Taxoids | 2012 |
[Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neurotoxicity Syndromes; Paclitaxel | 2004 |
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Nerve Growth Factor; Neurotoxicity Syndromes; Paclitaxel; Predictive Value of Tests; Prognosis; Sensation Disorders; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AG
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Humans; Neuroprotective Agents; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Placebos; Radiation-Protective Agents | 2005 |
Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Topics: Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Cell Count; Body Surface Area; Carboplatin; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Regression Analysis; Survival Analysis | 2008 |
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Drug Hypersensitivity; Ethanol; Female; Humans; Infant; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm, Residual; Neurotoxicity Syndromes; Paclitaxel; Polyethylene Glycols; Solvents | 2001 |
40 other study(ies) available for paclitaxel and Encephalopathy, Toxic
| Article | Year |
|---|---|
Mapping Drug-Induced Neuropathy through In-Situ Motor Protein Tracking and Machine Learning.
Topics: Animals; Antineoplastic Agents; Biological Transport; Fluorides; Ganglia, Spinal; Luminescent Agents; Metal Nanoparticles; Nerve Tissue Proteins; Neurons; Neurotoxicity Syndromes; Paclitaxel; Rats, Sprague-Dawley; Support Vector Machine; Thulium; Vincristine; Ytterbium; Yttrium | 2021 |
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients.
Topics: Adult; Biomarkers; Breast Neoplasms; Female; Humans; Intermediate Filaments; Middle Aged; Neurofilament Proteins; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Neural correlates in functional brain mapping among breast cancer survivors receiving different chemotherapy regimens: a qEEG/HEG-based investigation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Mapping; Breast Neoplasms; Cancer Survivors; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neurotoxicity Syndromes; Paclitaxel | 2022 |
Hinokitiol functions as a ferroptosis inhibitor to confer neuroprotection.
Topics: Animals; Ferroptosis; Mice; Monoterpenes; Neuroprotection; Neurotoxicity Syndromes; NF-E2-Related Factor 2; Paclitaxel; Tropolone; Zebrafish | 2022 |
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy.
Topics: Animals; Axons; Nerve Tissue; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats | 2023 |
[miR-99b-5p inhibits the activation of NLRP3 inflammasome to alleviate the neurotoxicity induced by paclitaxel chemotherapy].
Topics: Animals; Caspases; Inflammasomes; MicroRNAs; Neurotoxicity Syndromes; NLR Family, Pyrin Domain-Containing 3 Protein; Paclitaxel; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxide Dismutase | 2022 |
Evaluation of neurotoxicity of anticancer drugs using nematode Caenorhabditis elegans as a model organism.
Topics: Animals; Antineoplastic Agents; Caenorhabditis elegans; Cisplatin; Humans; Neurotoxicity Syndromes; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Vincristine | 2023 |
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
Topics: Adult; Aged; Cryotherapy; Docetaxel; Extremities; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Retrospective Studies; Treatment Outcome | 2020 |
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Axons; Biomarkers; Cisplatin; Disease Models, Animal; Female; Neurofilament Proteins; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Rats, Wistar; Severity of Illness Index; Up-Regulation | 2020 |
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Biomarkers; Disease Models, Animal; Disease Susceptibility; Humans; Hyperalgesia; Immunoglobulins, Intravenous; Macrophages; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Treatment Outcome | 2021 |
Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.
Topics: Breast Neoplasms; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2021 |
Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Colorectal Neoplasms; Female; Hemoglobins; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Obesity; Overweight; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors; Severity of Illness Index; Sex Factors; Young Adult | 2021 |
Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel-induced neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chromatography, Liquid; Drug Compounding; Ganglia, Spinal; Kinetics; Mice; Mice, Inbred C57BL; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Tandem Mass Spectrometry | 2021 |
TRPV4 inhibition prevents paclitaxel-induced neurotoxicity in preclinical models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcium Channels; Calcium Signaling; Cell Death; Cell Membrane; Endoplasmic Reticulum; Ganglia, Spinal; Immunohistochemistry; Inositol 1,4,5-Trisphosphate Receptors; Mice, Inbred C57BL; Neurotoxicity Syndromes; Paclitaxel; Rats; Rats, Wistar; Transfection; TRPV Cation Channels | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Oxaliplatin; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Surveys and Questionnaires | 2019 |
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Polymorphism, Single Nucleotide; Sex Characteristics | 2013 |
Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Cell Line; Drug Evaluation, Preclinical; Ethoxyquin; HSP90 Heat-Shock Proteins; Male; Mice; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Paclitaxel | 2013 |
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Neurotoxicity Syndromes; Paclitaxel | 2014 |
Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.
Topics: Adult; Antineoplastic Agents; Brazil; Cross-Sectional Studies; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Psychometrics; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2014 |
Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Topics: Adult; Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neurotoxicity Syndromes; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2014 |
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Computer Simulation; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Neurotoxicity Syndromes; Paclitaxel; Young Adult | 2015 |
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Carboplatin; Carrier Proteins; Colony-Stimulating Factors; DNA Repair; Female; Genotype; Hematinics; Humans; Inactivation, Metabolic; Middle Aged; Multidrug Resistance-Associated Protein 2; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Thrombocytopenia; Young Adult | 2015 |
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Topics: Alleles; Amodiaquine; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Isoenzymes; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone; Substrate Specificity; Thiazolidinediones | 2015 |
Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Ticlopidine | 2016 |
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Incidence; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Surveys and Questionnaires | 2009 |
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Disease Models, Animal; Drug Administration Schedule; Female; Ganglia, Spinal; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Weight Loss | 2009 |
Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; G(M1) Ganglioside; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Sensation | 2009 |
Tracing the incidence of paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Reproducibility of Results | 2009 |
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Topics: Aged; Alleles; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Female; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Spain | 2011 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Motor Neuron Disease; Neoplasm Staging; Neurophysiology; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Axons; Disease Models, Animal; Drosophila; Drosophila Proteins; Eye Proteins; Female; Ganglia, Spinal; Immunohistochemistry; Larva; Mice; Microscopy, Confocal; Nerve Degeneration; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nerves; RNA Interference | 2012 |
Paclitaxel increases high voltage-dependent calcium channel current in dorsal root ganglion neurons of the rat.
Topics: Action Potentials; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cell Size; Cells, Cultured; Ganglia, Spinal; Hyperalgesia; Male; Nerve Tissue Proteins; Neuralgia; Neurons; Neurotoxicity Syndromes; Paclitaxel; Rats; Rats, Wistar; Up-Regulation | 2012 |
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.
Topics: Aged; Antineoplastic Agents, Phytogenic; Biopsy; Female; Humans; Male; Mechanoreceptors; Middle Aged; Motor Skills; Nerve Fibers; Neurotoxicity Syndromes; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Physical Stimulation; Pilot Projects; Sensory Thresholds; Skin; Thermosensing; Touch; Vincristine | 2013 |
Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine.
Topics: Adenocarcinoma; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Phytogenic; Cyclohexanols; Female; Humans; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Paresthesia; Sensation Disorders; Venlafaxine Hydrochloride | 2002 |
Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pleurodynia, Epidemic; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome; Women's Health | 2003 |
Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel.
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents, Phytogenic; Cell Nucleolus; Cell Size; Disease Models, Animal; Female; Ganglia, Spinal; H-Reflex; Immunohistochemistry; Neural Conduction; Neurons, Afferent; Neuropeptide Y; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; Reaction Time; Up-Regulation | 2007 |
Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Laryngeal Nerves; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Vinblastine; Vinorelbine; Vocal Cord Paralysis | 2008 |
Carrier effects on antitumor activity and neurotoxicity of AZ10992, a paclitaxel-carboxymethyl dextran conjugate, in a mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemical Phenomena; Chemistry, Physical; Dextrans; Dose-Response Relationship, Drug; Drug Carriers; Female; Male; Mice; Mice, Inbred BALB C; Molecular Weight; Neurotoxicity Syndromes; Paclitaxel; Rats; Rats, Wistar; Sciatic Nerve; Tissue Distribution | 2008 |
Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study.
Topics: Action Potentials; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Body Weight; Electrophysiology; Ganglia, Spinal; Injections, Intraperitoneal; Male; Mice; Nerve Degeneration; Nerve Fibers; Neuropeptides; Neurotoxicity Syndromes; Paclitaxel; Pain Threshold; Sciatic Nerve | 2000 |